Once-daily dosing of Merck's Isentress fails in HIV
This article was originally published in Scrip
Executive Summary
Merck has hit another setback in its development of its HIV drugs, after it halted on efficacy grounds a Phase III study comparing an investigational once-daily dose of its integrase inhibitor Isentress (raltegravir) with the approved twice-daily dose in treatment-naïve HIV-1 infected patients.